Belafarm SPRL
Sursis (réorganisation judiciaire) 0.8 FTEBelafarm reported total assets of 292,531 € at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Sep 2026), with 0.8 full-time equivalent.
The score of Belafarm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -49 % Headcount (avg FTE) -43 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Belafarm's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Sep 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 21 Feb 2025
- Year ended 31 Dec 2022filed on 14 Jun 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Belafarm's financial analysis
- Solvency-35.4%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Belafarm
Belafarm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0642.541.559
- VAT number
- BE0642541559
- Peppol
- Registered · 0208:0642541559 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 30 Oct 2015
- Registered office
- 6040 Charleroi
- Size
- Micro · 0.8 FTE
- Latest accounts
- 2025 · filed on 22 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Belafarm (SPRL) has been based in Charleroi since 2015, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 140 € and equity of −103,558 €; its revenue is not published. With 0.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -35.4%, below the median of its sector (41.5%).
Companies similar to Belafarm
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Fontaine Retail sale of pharmaceutical products Charleroi · balance sheet 297,453 €
- LES Iles D'OR Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet 291,796 €
- Askela Retail sale of pharmaceutical products Chièvres · balance sheet 293,294 €
- Aksa Pharma Retail sale of pharmaceutical products Brussels · balance sheet 293,776 €
- Theunissen-DE Neve Retail sale of pharmaceutical products Aalst · balance sheet 291,003 €
- AONA Retail sale of pharmaceutical products Roeselare · balance sheet 290,456 €
- ACE Pharma Retail sale of pharmaceutical products Fexhe-le-Haut-Clocher · balance sheet 289,661 €
- Leveugle Retail sale of pharmaceutical products Deinze · balance sheet 297,608 €
Frequently asked questions about Belafarm
What is the revenue of Belafarm?
Belafarm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Belafarm?
In Belgium, the VAT number is the company number prefixed with BE: BE0642541559 for Belafarm, if the company is VAT-registered. Its company number (CBE) is 0642.541.559.
Where is the registered office of Belafarm?
According to the CBE register, the registered office of Belafarm is in 6040 Charleroi.
What is the equity of Belafarm?
At the close of the 2025 financial year, the equity of Belafarm amounts to -103,558 €, a solvency of -35.4% of total assets.
How many people work at Belafarm?
0.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Belafarm?
The register lists 1 active mandates at Belafarm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Belafarm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →